Atypicals Antidepressants
Atypical antidepressants are a diverse group of medications that don’t fit neatly into SSRI or SNRI categories and work through varied neurotransmitter mechanisms. Examples include Remeron (mirtazapine), which affects serotonin and norepinephrine receptors and is often associated with sedation and appetite changes, and trazodone, which is commonly used at low doses for sleep due to its sedating effects. Vortioxetine (Trintellix) is sometimes grouped with atypicals and is known for its multimodal action on serotonin receptors and potential cognitive effects. These medications are used for depression, anxiety, and sleep-related symptoms, especially when standard antidepressants are poorly tolerated. Responses can vary widely, and side effect profiles differ substantially between agents.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, mirtazapine, trazodone, and vortioxetine are discussed in relation to their potential interactions with serotonergic, adrenergic, and histamine signaling pathways. Mirtazapine increases norepinephrine and serotonin release primarily via α2-adrenergic blockade and also antagonizes 5-HT2/5-HT3 receptors and H1 histamine receptors. Trazodone is commonly categorized as a SARI (serotonin antagonist/reuptake inhibitor): it antagonizes 5-HT2A receptors and inhibits serotonin reuptake, and it also blocks α1-adrenergic and H1 receptors. Vortioxetine inhibits the serotonin transporter (SERT) and modulates multiple serotonin receptors. These mechanisms may interact with pathways involving serotonin, norepinephrine, or histamine signaling that are often discussed in relation to PFS / PSSD / PAS.
-
Reports of Severe and Sometimes Lasting Worsening (for PFS/PSSD/PAS):
Among individuals who already have PFS/PSSD/PAS, mirtazapine, trazodone, and vortioxetine are approached with significant caution as they are frequently cited in community reports as preceding symptom worsening, with accounts describing both acute exacerbations and longer-lasting declines in baseline. Although the severity and duration of these reactions vary between individuals, reports within this subgroup show a largely consistent direction toward worsening rather than improvement. In light of this pattern, many within the community view mirtazapine, trazodone, and vortioxetine as carrying a meaningful risk for those with established PFS/PSSD/PAS, even in the absence of controlled data.
For individuals without these conditions, these medications are widely prescribed and beneficial for many, but there are still reports of adverse effects in a subset of users including developing PSSD-like symptoms.
Evidence basis: Established pharmacology and interaction literature; mainstream medical safety guidance; anecdotal reports (online forums, self-reports); no controlled studies examining PFS/PSSD/PAS-specific outcomes.
-
Crash / Baseline Drops (Reported)
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.